Breast Cancer

, Volume 4, Issue 4, pp 256–258

BRCA1 andBRCA2 germline mutations in Japanese with hereditary breast cancer families

  • Takashi Fukutomi
  • Toshikazu Ushijima
  • Rie Inoue
  • Sadako Akashitanaka
  • Takeshi Nanasawa
  • Hitoshi Tsuda
Symposium I

DOI: 10.1007/BF02966517

Cite this article as:
Fukutomi, T., Ushijima, T., Inoue, R. et al. Breast Cancer (1997) 4: 256. doi:10.1007/BF02966517

Abstract

We examined germline mutations inBRCA1 andBRCA2 in 23 Japanese breast cancer families, using PCR-SSCP analysis. The same nonsense mutation (exon 5, Leu63ter) ofBRCA1 was detected in two different families. Three different mutations resulting in a truncatedBRCA2 protein (exon 9, 20, 24) were detected in three different families, including one male case of breast cancer. One base substitution mutation inBRCA2, A10462G, was detected in the other two families. Although the mean age of onset for breast cancer in families with theBRCA1- mutation was 50 years, the age of onset in families with theBRCA2-mutation was from 28 to 43 years. Among the 23 families examined, two families had members with ovarian cancers, three had members with prostate cancers, and one had a pancreatic cancer. However, none of these families was positive for theBRCA1 orBRCA2 mutation. Histopathologically, we observed a prevalence of histological grade 3 inBRCA2-associated familial breast cancers, because of nuclear atypia, structural atypia and mitotic activity. It is suggested thatBRCA2 may play a more important role thanBRCA1 in Japanese familial breast cancers, and these mutations are related to the aggressive nature and highly proliferative activity of the tumors.

Key words

BRCA1BRCA2Hereditary breast cancerHistological grade

Copyright information

© The Japanese Breast Cancer Society 1997

Authors and Affiliations

  • Takashi Fukutomi
    • 1
  • Toshikazu Ushijima
    • 2
  • Rie Inoue
    • 2
  • Sadako Akashitanaka
    • 1
  • Takeshi Nanasawa
    • 1
  • Hitoshi Tsuda
    • 3
  1. 1.Department of SurgeryNational Cancer Center HospitalTokyoJapan
  2. 2.Carcinogenesis DivisionNational Cancer Center Research InstituteJapan
  3. 3.Pathology DivisionNational Cancer Center Research InstituteJapan